En Ze Jia Shi Pharmaceuticals, a wholly owned subsidiary of Lotus Pharmaceuticals, has received patent from the State Intellectual Property Office of the People's Republic of China, which covers the composition and preparation methods for controlled-release oral Gliclazide through 2030.

Gliclazide is commonly used to control mild to moderate adult-onset type 2 diabetes.

Lotus Pharma’s new controlled-release Gliclazide tablet is formulated using osmotic pump technology, which encases the drug in a semi-permeable framework for a gradual, sustained release.

Lotus Pharma chairman and CEO Zhongyi Liu said that they believe their controlled-release Gliclazide tablet would have a meaningful impact on the clinical treatment of diabetes.

“Our controlled-release formulation has the potential to provide a more stable and sustained drug delivery compared to conventional Gliclazide, resulting in fewer side effects, greater efficacy and an improved safety profile,” Liu said.